{
    "clinical_study": {
        "@rank": "45115", 
        "arm_group": {
            "arm_group_label": "No treatment", 
            "description": "Subjects diagnosed with Dystrophic Epidermolysis Bullosa"
        }, 
        "brief_summary": {
            "textblock": "The objective of this study is to characterize the extent and severity of disease in\n      subjects with DEB and the progression of disease over a timeframe relevant to interventional\n      studies.  The data from this study will be used to inform the study design and address\n      statistical considerations of future treatment protocols."
        }, 
        "brief_title": "Prospective, Longitudinal Natural History Study in Dystrophic Epidermolysis Bullosa", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Dystrophic Epidermolysis Bullosa", 
        "condition_browse": {
            "mesh_term": [
                "Epidermolysis Bullosa", 
                "Epidermolysis Bullosa Dystrophica"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a prospective, multicenter, multinational, longitudinal assessment of disease\n      severity in subjects with DEB.  Subjects with either dominant or recessive DEB (dominant\n      dystrophic epidermolysis bullosa (DDEB) and recessive dystrophic epidermolysis bullosa\n      (RDEB), respectively) will be assessed four times over a one year period: upon enrollment,\n      and at 1 to 2 weeks and 6 and 12 months after enrollment.  All subjects with either DDEB or\n      RDEB that meet the study entry criteria will be offered participation in the study, provided\n      they can be accommodated within the anticipated study timeline.  In addition to their usual\n      clinic assessment, subjects will have a quantitative evaluation of skin involvement and will\n      be asked to fill out questionnaires that measure among other things disease severity, QOL,\n      pain, pruritus, and medical and family histories."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Eligibility Criteria\n\n          -  Subjects of any age (newborns included) may participate\n\n          -  Subjects over 18 years of age and parent(s)/legal guardian(s) of subjects <18 years\n             of age must provide written informed consent prior to participating in the study and\n             informed assent will be obtained from minors at least 7 years of age\n\n          -  Subjects must have a documented diagnosis of DEB based on clinical presentation and\n             either skin biopsy results showing an absence or reduction in C7 or anchoring fibrils\n             or genetic analysis showing a mutation in collagen, type VII, alpha 1 (Col7A1);\n             alternatively, subjects must have a clinical diagnosis of DEB and a documented\n             diagnosis of DEB (as above) in a first degree relative\n\n          -  No experimental systemic therapy for DEB including, but not limited to, bone marrow\n             transplantation, systemic immune suppression, or experimental therapies that involve\n             live cells which have the potential for systemic spread such as gene transfer, stem\n             cell infusions or other cell type injections"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients will be selected from clinical sites with interdisciplinary clinics for\n        Dystrophic Epidermolysis Bullosa"
            }
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01768026", 
            "org_study_id": "DEB-101-12"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Dystrophic Epidermolysis Bullosa", 
            "Type VII Collagen", 
            "QOL Evaluation in Epidermolysis Bullosa", 
            "Instrument for Scoring Clinical Outcomes for Research of Epidermolysis Bullosa", 
            "Birmingham Epidermolysis Bullosa Severity Score"
        ], 
        "lastchanged_date": "May 20, 2013", 
        "link": [
            {
                "description": "Dystrophic Epidermolysis Bullosa Research Association of America (DEBRA)", 
                "url": "http://www.debra.org/"
            }, 
            {
                "description": "EB Care Patient Reported Registry", 
                "url": "https://ebcare.patientcrossroads.org/"
            }, 
            {
                "description": "Lotus Tissue Repair, Inc.", 
                "url": "http://www.lotustissuerepair.com/"
            }, 
            {
                "description": "Dystrophic Epidermolysis Bullosa Research Association International", 
                "url": "http://www.debra-international.org/homepage.html"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Palo Alto", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94304"
                }, 
                "name": "Stanford University School of Medicine"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Prospective, Longitudinal Assessment of Disease Severity in Subjects With Dystrophic Epidermolysis Bullosa (DEB)", 
        "overall_official": {
            "affiliation": "Lotus Tissue Repair, Inc.", 
            "last_name": "Hal Landy, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Disease severity and its impact on quality of life and function will be investigated over a one year period at the following timepoints: upon enrollment, and at 1 to 2 weeks and 6 and 12 months after enrollment.", 
            "measure": "Characterize the progression of disease severity in subjects with DEB over 6 - 12 months.", 
            "safety_issue": "No", 
            "time_frame": "One year period"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01768026"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Lotus Tissue Repair, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lotus Tissue Repair, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "February 2013"
    }
}